Energy Expenditure From ECAL Indirect Calorimeter in a Multicomponent Weight Management Service

Obesity Clinical Trial

— ECAL  

Official title:

Randomised Controlled Trial to Evaluate Impact of Energy Expenditure Information on the Outcome of Weight Loss During a Standardised Multicomponent Weight Management Intervention

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03638895
• Other study ID #: UoL001379
• Status: Completed
• Phase: N/A
• Start date: November 28, 2018
• Est. completion date: August 25, 2022

Study information

• Verified date: July 2023
• Source: University of Liverpool
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Whether greater weight loss is as a result of a smaller reduction in energy expenditure with caloric restriction is not known. Resting energy expenditure and 24-hour energy expenditure vary substantially between individuals. In some cases, relatively reduced rates of 24h EE predict weight gain in some populations who have high prevalence of obesity. Obese individuals that lose weight experience a decrease in 24-h EE and resting energy expenditure that is lower than predicted based on changes in body composition. Most weight loss studies have found a large individual variation in the amount of weight change, and whether an individual's response to an intervention can be predicted is not clear. Measurements of 24-hour EE in response to fasting may help predict weight loss. The ECAL indirect calorimeter (ECAL) is a validated device purpose-built to provide the practitioner and patient with energy information that allows for more accurate, reliable method of establishing an obese individuals' metabolic profile. The aim of this study is to determine whether providing energy information from ECAL indirect calorimeter as an adjunct to the multicomponent weight management intervention in non-diabetic obese and severely obese individuals would help predict the response of weight loss.

Description:

Weight loss is important to improve overall health and reduce risk of obesity-related comorbidities such as diabetes. Numerous studies performed on individuals with predisposed genetic propensity to obesity who are deemed to be metabolically 'thrifty', require further structured intensification of caloric restriction and change in physical activity in order to achieve weight loss. Whether greater weight loss is as a result of smaller reduction in energy expenditure with calorie restriction is not known. Resting energy expenditure and 24-hour energy expenditure vary substantially between individuals. Obese individuals that lose weight experience a decrease in 24-h EE and resting energy expenditure that is lower than predicted based on changes in body composition. Most weight loss studies have found a large individual variation in the amount of weight change, and whether an individual's response to an intervention can be predicted is not clear. Measurements of 24-hour EE in response to fasting may help predict weight loss. The ECAL indirect calorimeter (ECAL) is a validated device purpose-built to provide the practitioner and patient with energy information that allows for more accurate, reliable method of establishing an obese individuals' metabolic profile. The ECAL device also measures the respiratory quotient (RQ) which is the ratio of the volume of carbon dioxide expired to that of oxygen consumed by the individual for every breath. Previous studies demonstrated variability in role of RQ in predicting weight loss, but individuals who demonstrated an RQ in the lower range (<0.72) were more likely to maintain the weight-loss achieved on a caloric restriction and avoid a weight loss rebound as compared to those with RQ in the higher range (>0.75). This suggests that RQ could prove useful in clinical practice as a prognostic marker for long-term effectiveness of low- and very-low-calorie diets used to induce weight loss. Baltimore Longitudinal Study on Aging shared a similar finding that fasting RQ or respiratory exchange ratio adjusted for age, BMI, and fat free mass was positively related to weight change. The aim of this study is to determine whether providing energy information from ECAL indirect calorimeter as an adjunct to the multicomponent weight management intervention in non-diabetic obese and severely obese individuals would help predict the response of weight loss.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 51
• Est. completion date: August 25, 2022
• Est. primary completion date: August 25, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• BMI > or equivalent to 30 kg/m2 to - 60 kg/m2

• Stable weight (change of <5% within 12 weeks before screening based on medical history)

• Subjects are well-motivated, capable and willing to learn how to undergo indirect calorimetry testing

• Willing and able to adhere to prohibitions and restrictions specified within this protocol

For Subjects participating in the glycaemic variability sub-study:

• Subject understands instructions on the use of continuous glucose monitor sensor and is willing to undergo appropriate training and testing

Exclusion Criteria:

• Taking weight loss medication within 12 weeks prior to randomisation

• Previous or planned bariatric surgery

• History of Type 1, Type 2 diabetes mellitus, DKA or diabetes secondary to pancreatitis

• Has HbA1c > or equal to 6.5% or Fasting Plasma Glucose > or equal to 7.0 mmol/L at screening.

NOTE: a one-time repeat measurement is allowed, if value of HbA1c and/or FPG is not consistent with prior values

• History of obesity with a known secondary cause (Cushing's disease/syndrome)

• Oral corticosteroid use (except in the short term use of a 7-10 day course)

• Ongoing, inadequately controlled thyroid disorder defined as thyroid-stimulating hormone > 6 mIU/litre or < 0.4 mIU/litre

• History of malignancy within 3 years before screening (or diagnosis of malignancy within this period)

• estimated glomerular filtration rate < 30 ml/min/1.73m2 on serum testing

• Alanine aminotransferase level is <2.0 times the upper limit of normal or total bilirubin is >1.5 times the upper limit of normal at screening

• Other major illness likely to preclude participation in the trial

• History of glucagonoma

• A myocardial infarction, unstable angina, revascularisation procedure (stent or bypass graft surgery) or cerebrovascular accident within 12 weeks before screening

Related Conditions & MeSH terms

• Obesity
• Obesity, Morbid
• Severe Obesity
• Sleep Apnoea

Intervention

Device:
• ECAL Indirect Calorimeter
The ECAL is an open-circuit portable indirect calorimeter that measures both volume of CO2 expired and O2 consumed using a small mixing chamber. Participants will breathe through a mouthpiece with a nose clip applied whilst lying in a restful and comfortable position for 15 minutes. ECAL device will provide breath-by-breath measurements of the resting energy expenditure and respiratory quotient which will allow both practitioners and participants to monitor their metabolic health and compare the effect of dietary and physical activity intervention over the course of the structured intensive lifestyle intervention (24-weeks).

Behavioral:
• Diet, exercise & behaviour modification therapy
Standard care (SC) - participants receive standard care (diet, exercise & behaviour modification therapy) as part of the multicomponent weight management intervention within the tier 3 weight management service. Practitioners will rely on standard predictive equations to provide dietary advice and intervention.

Locations

Country	Name	City	State
United Kingdom	University Hospital Aintree	Liverpool

Sponsors (2)

Lead Sponsor	Collaborator
University of Liverpool	Metabolic Health Solutions UK

Country where clinical trial is conducted

United Kingdom, 

References & Publications (6)

Alves VG, da Rocha EE, Gonzalez MC, da Fonseca RB, Silva MH, Chiesa CA. Assessement of resting energy expenditure of obese patients: comparison of indirect calorimetry with formulae. Clin Nutr. 2009 Jun;28(3):299-304. doi: 10.1016/j.clnu.2009.03.011. Epub 2009 Apr 23. — View Citation

Das SK, Saltzman E, McCrory MA, Hsu LK, Shikora SA, Dolnikowski G, Kehayias JJ, Roberts SB. Energy expenditure is very high in extremely obese women. J Nutr. 2004 Jun;134(6):1412-6. doi: 10.1093/jn/134.6.1412. — View Citation

Lam YY, Ravussin E. Indirect calorimetry: an indispensable tool to understand and predict obesity. Eur J Clin Nutr. 2017 Mar;71(3):318-322. doi: 10.1038/ejcn.2016.220. Epub 2016 Nov 16. — View Citation

McLay-Cooke RT, Gray AR, Jones LM, Taylor RW, Skidmore PML, Brown RC. Prediction Equations Overestimate the Energy Requirements More for Obesity-Susceptible Individuals. Nutrients. 2017 Sep 13;9(9):1012. doi: 10.3390/nu9091012. — View Citation

Melo CM, Tirapegui J, Ribeiro SM. [Human energetic expenditure: concepts, assessment methods and relationship to obesity]. Arq Bras Endocrinol Metabol. 2008 Apr;52(3):452-64. doi: 10.1590/s0004-27302008000300005. Portuguese. — View Citation

Wang X, Wang Y, Ding Z, Cao G, Hu F, Sun Y, Ma Z, Zhou D, Su B. Relative validity of an indirect calorimetry device for measuring resting energy expenditure and respiratory quotient. Asia Pac J Clin Nutr. 2018;27(1):72-77. doi: 10.6133/apjcn.032017.02. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Magnitude of weight loss (in kg)		6 months
Secondary	Resting metabolic rate (RMR)	The measurement of number of calories that the body burns at rest in 24 hours, expressed as kcal/day	6 months
Secondary	Respiratory Quotient (RQ)	The ratio of carbon dioxide production to oxygen consumption and reflects the relative contribution of fat, carbohydrate, and protein in the oxidation fuel mixture.	6 months
Secondary	Secretion of gut hormones (GLP-1, GIP, PYY)	Secretion of appetite regulating gut hormone (GLP-1, GIP, PYY) in fasting and post-prandial phase	6 months
Secondary	Glycaemic variability	Change from baseline in the swings in blood glucose levels, expressed as the mean amplitude of glycaemic excursion (MAGE)	6 months
Secondary	Insulin sensitivity	Change from baseline in the measure of insulin rise in response to blood sugar levels, expressed as the homeostasis model assessment (HOMA). HOMA estimates steady state beta cell function and insulin sensitivity as percentages of the normal reference population.	6 months
Secondary	Sensory Neuropathy Testing in Prediabetic Obese Individuals	Change from baseline in vibration perception threshold measurement using the neurothesiometer	6 months
Secondary	Douleur Neuropathique en4 Questions (DN4)	Change from baseline in Douleur Neuropathique en4 Questions (DN4) using seven interview questions and three physical tests.	6 months
Secondary	Visual analogue score	Change from baseline in visual analogue score of pain, expressed as Units on a scale of 0 to 100. where 0 is worst possible health and 100 is the best possible health.	6 months
Secondary	modified Total Neuropathy Score	Change from baseline in modified Total Neuropathy Score (mTNS) questionnaire expressed as the average of the five components	6 months
Secondary	Brief Pain Inventory Short Form	Change from baseline in brief pain inventory short form (BPI-SF) scored as the mean of the seven interference items.	6 months